{"Ticker": "VRTX", "Company": "Vertex Pharmaceuticals", "Sector": "Health Care", "Updated": "2022-01-20", "Rating": [{"Date": "2022-01-20", "Rating": "Upgrade", "Organization": "BMO Capital Markets", "Rating_Change": "Market Perform to Outperform", "Target_Change": "$202 to $274"}, {"Date": "2021-12-09", "Rating": "Initiated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$270"}, {"Date": "2021-11-19", "Rating": "Initiated", "Organization": "BMO Capital Markets", "Rating_Change": "Market Perform", "Target_Change": "$202"}, {"Date": "2021-11-19", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$323 to $218"}, {"Date": "2021-09-09", "Rating": "Downgrade", "Organization": "Stifel", "Rating_Change": "Buy to Hold", "Target_Change": "$244 to $213"}, {"Date": "2021-09-07", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight to Underweight", "Target_Change": "$202"}, {"Date": "2021-07-20", "Rating": "Downgrade", "Organization": "SVB Leerink", "Rating_Change": "Mkt Perform to Underperform", "Target_Change": "$170"}, {"Date": "2021-07-19", "Rating": "Resumed", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$252"}, {"Date": "2021-07-01", "Rating": "Initiated", "Organization": "Raymond James", "Rating_Change": "Mkt Perform", "Target_Change": ""}, {"Date": "2021-06-11", "Rating": "Downgrade", "Organization": "Daiwa Securities", "Rating_Change": "Outperform to Neutral", "Target_Change": "$210"}, {"Date": "2021-02-23", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Neutral to Outperform", "Target_Change": "$220 to $252"}, {"Date": "2021-02-02", "Rating": "Reiterated", "Organization": "H.C. Wainwright", "Rating_Change": "Buy", "Target_Change": "$315 to $275"}, {"Date": "2020-12-30", "Rating": "Initiated", "Organization": "Daiwa Securities", "Rating_Change": "Outperform", "Target_Change": "$250"}, {"Date": "2020-11-30", "Rating": "Upgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Sector Perform to Outperform", "Target_Change": "$247 to $267"}, {"Date": "2020-11-20", "Rating": "Initiated", "Organization": "Bernstein", "Rating_Change": "Outperform", "Target_Change": "$225"}, {"Date": "2020-10-28", "Rating": "Initiated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$287"}, {"Date": "2020-07-31", "Rating": "Reiterated", "Organization": "H.C. Wainwright", "Rating_Change": "Buy", "Target_Change": "$295 to $315"}, {"Date": "2020-07-08", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$300"}, {"Date": "2020-04-30", "Rating": "Reiterated", "Organization": "H.C. Wainwright", "Rating_Change": "Buy", "Target_Change": "$270 to $295"}, {"Date": "2020-04-28", "Rating": "Downgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform to Sector Perform", "Target_Change": "$250 to $260"}, {"Date": "2020-03-04", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$271"}]}